Plasmapheresis in Treatment of Human T-Lymphotropic Virus Type-I Associated Myelopathy
Lancet 2:1109-1113, Matsuo,H.,et al, 1988
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Morvan Syndrome: Clinical and Serological Observations in 29 Cases
Ann Neurol 72:241-255, Irani, S.R.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Plasmapheresis Improves Outcome in Postinfectious Cerebellitis Induced by Epsteiin-Barr Virus
Neurol 62:1443, Schmahmann,J.D., 2004
Prognostic Factors of Guillain-Barre Syndrome After Intravenous Immunoglobulin or Plasma Exchange?
Neurol 53:598-604, Visser,L.H.,et al, 1999
Plasmapheresis and Antineoplastic Treatment in CNS paraneoplastic Syndromes with Antineuronal Autoantibodies
Neurol 42:536-540, Graus,F.,et al, 1992
Plasmapheresis in the Treatment of Stiff-Man Syndrome
NEJM 320:1499, Vicari,A.M.,et al, 1989